J.Jill Q2 profit rises but H1 sales, margins fall as SG&A climbs

Quick take - J.Jill, Inc. (NYSE: JILL)

All dollar amounts below are reported figures from the company's Form 10‑Q (amounts shown in the filings are in thousands unless otherwise noted).

What's happening inside the company - snapshot

* Net sales are roughly flat to down vs. prior year: Thirteen weeks ended Aug 2, 2025 - $153,987; Twenty‑six weeks - $307,611 (down vs. $155,242 and $316,755, respectively).

* Profitability mixed: Qtr net income improved year‑over‑year while half‑year slipped - Net income (13 weeks) $10,515 vs $8,191 (+28.4%); Net income (26 weeks) $22,207 vs $24,887 (‑10.8%).

* Gross margin compression: 13‑week gross margin 68.4% vs 70.5% prior year; 26‑week 70.1% vs 71.7% - driven by higher markdown mix, promotions and tariffs.

* SG&A pressure: SG&A rose in absolute terms and as % of sales - 13 weeks SG&A $88,569 (57.5% of sales) vs $86,314 (55.6%); 26 weeks $179,657 (58.4%) vs $175,426 (55.4%).

* Strong cash balance and liquidity: Cash & cash equivalents $45,523 (Aug 2, 2025); cash, cash equivalents & restricted cash reported in cash flow $45,886. Available ABL capacity $35.7M.

* Debt position: Net long‑term Term Loan (due 2028) on balance sheet $70,016 (carrying value); remaining principal noted as $74,288 with net long‑term debt $70,016. In compliance with covenants.

* Shareholder returns: Company repurchased 255,240 shares YTD for $4.5M; as of Aug 2, 2025 had $20.0M remaining repurchase authorization. Quarterly dividend declared and paid $0.08 per share (paid and declared subsequent).

* Working capital / inventories: Inventories, net $55,268 (down from $61,295 at Feb 1, 2025); Accounts payable $47,236 (down from $51,980).

* Balance sheet: Total assets $436,508; Total liabilities $315,007; Total shareholders' equity $121,501; Accumulated deficit $(114,435).

* Intangibles & goodwill: Goodwill $59,697; total intangible assets carrying amount $58,669; accumulated goodwill impairment losses disclosed $137,300 (existing accumulated impairment).

Positive aspects of the income statement / financials

* Improved quarterly earnings and EPS: 13‑week net income $10,515 with basic EPS $0.69 (vs $0.55 prior year).

* Lower interest burden: Interest expense down materially (13 weeks $2,733 vs $3,724; 26 weeks $5,522 vs $10,160) after prior principal prepayments.

* Strong operating cash generation (still positive): Net cash provided by operating activities $24,698 for 26 weeks (though lower than prior year).

* Active capital returns: Dividend program maintained ($0.08 per share) and share repurchases in place - signal of board confidence and use of excess cash.

Negative aspects of the income statement / financials

* Sales pressure and margin shrink: Net sales down 2.9% for the 26‑week period and gross margin compression (higher markdowns/promotions and tariffs) reduced gross profit by $11.4M year‑over‑year for 26 weeks.

* Rising operating leverage / SG&A as a % of sales: SG&A increased in dollars and jumped ~300 bps as a % of sales for the 26‑week period, pressuring operating income (Operating income 26 weeks $35,845 vs $51,394 prior year).

* Lower half‑year net income: 26‑week net income declined to $22,207 from $24,887; operating income down ~30% (reflects margin and expense pressures).

* Decline in operating cash flow vs prior year: Operating cash flow declined from $37,880 to $24,698 for the 26‑week periods - driven by working capital movements (AP and accrued liabilities declines).

* Legacy impairment and intangible concerns: Large accumulated goodwill impairment ($137,300) remains on the balance sheet - a reminder of past write‑downs and sensitivity to future impairment triggers.

Key metrics & KPIs (as reported)

* Net sales - 13 weeks: $153,987; 26 weeks: $307,611.

* Gross profit - 13 weeks: $105,357; 26 weeks: $215,714.

* Net income - 13 weeks: $10,515; 26 weeks: $22,207.

* Basic EPS - 13 weeks: $0.69; 26 weeks: $1.45.

* Adjusted EBITDA - 13 weeks: $25,589 (Adjusted EBITDA margin 16.6%); 26 weeks: $52,924 (margin 17.2%).

* Cash & cash equivalents (Aug 2, 2025): $45,523; Cash, cash equivalents & restricted cash (cash flow end): $45,886.

* Inventories, net (Aug 2, 2025): $55,268.

* Accounts receivable: $6,478; Accounts payable: $47,236; Accrued expenses & other current liabilities: $31,588.

* Total assets: $436,508; Total liabilities: $315,007; Shareholders' equity: $121,501.

* Term loan remaining principal (reported): $74,288 (net long‑term debt $70,016 carrying value). ABL availability $35.7M; letters of credit outstanding $4.3M.

* Share repurchases: 68,440 shares repurchased in the most recent quarter; 255,240 shares YTD for $4.5M. Remaining buyback capacity $20.0M.

* Dividend: $0.08 per share declared and paid in July; Board declared $0.08 on Aug 27, 2025 payable Oct 1, 2025.

What to watch next (near term)

* Margin recovery vs. continued promotional pressure and tariffs - will the company regain full‑price mix?

* SG&A control and operating leverage - management must bend SG&A lower as sales pressure persists to restore operating income.

* Cash flow trends and working capital (AP and accrued liabilities movements) - operating cash flow dropped YoY and is key for buybacks/dividends.

* Debt maturity and refinancing risk - Term Loan matures May 8, 2028; monitor any refinancing activity and covenant compliance.

* Impairment triggers - watch store performance, goodwill/intangible impairment indicators given substantial prior impairments.

Bottom line: J.Jill shows resilient quarterly profitability and a healthy cash position, but sales softness, margin compression and rising SG&A as a percent of sales are weighing on half‑year results. Management's focus should be on margin restoration, SG&A discipline and preserving operating cash flow while supporting shareholder returns.